
FEE TRANSMITTA

APR 2 9 2002

Patent fees are subject to annual evision.

TOTAL AMOUNT OF PAYMENT



METHOD OF PAYMENT (Check one)	FEE CALCULATION (continued)			
1. The Commissioner is hereby authorized to charge indicated fees and credit any overpayments to:	3. ADDITIONAL FEES			
Deposit Account Number 13-2755	Large Entity Fee Fee Fee Description Fee Paid Code (\$)			
Deposit Account Merck & Co., Inc.	105 130 Surcharge - late filing fee or oath			
Charge Any Additional Fee Required Under 37 CFR 1.16 and 1.17	147 2,520 For filing a request for reexamination			
_	115 110 Extension for reply within first month			
2. Payment Enclosed:	116 400 Extension for reply within second month			
Check Money Order Other	117 920 Extension for reply within third month			
FEE CALCULATION	118 1,440 Extension for reply within fourth month			
1. BASIC FILING FEE	128 1,960 Extension for reply within fifth month			
Large Entity Fee Fee Fee Description Fee Paid	119 320 Notice of Appeal			
Code (\$) 101 740 Utility filing fee	120 320 Filing a brief in support of an appeal			
106 330 Design filing fee	121 280 Request for oral hearing			
108 740 Reissue filing fee	140 110 Petition to revive - unavoidable			
114 160 Provisional filing fee	141 1,280 Petition to revive - unintentional			
114 100 Provisional fining fee	142 1,280 Utility issue fee (or reissue)			
SUBTOTAL(1) \$0	143 460 Design issue fee			
2. EXTRA CLAIM FEES	122 130 Petitions to the Commissioner			
Extra Fee from Fee Paid below	123 50 Petitions related to provisional applications			
Total Claims - 20 ** = 0 x \$18 = 0 Independent - 3 ** = 0 x \$84 = 0	126 180 Submission of Information Disclosure 180 Statement			
Multiple Dependent Claims \$280 =	581 40 Recording each patent assignment per property (times number of properties)			
**or number previously paid, if greater; For Reissues, see below Large Entity	146 740 Filing a submission after final rejection (37 CFR 1.129(a))			
Fee Fee Fee Description Code (\$) 103 18 Claims in excess of 20	149 740 For each additional invention to be examined (37 CFR 1.129(b))			
102 84 Independent claims in excess of 3	179 740 Request for Continued Examination (RCE)			
104 280 Multiple dependent claim, if not paid	(NCL)			
109 84 **Reissue independent claims over original patent	Other fee (specify)			
110 18 **Reissue claims in excess of 20 and over original patent	Other fee (specify)			
SUBTOTAL(2) \$0	SUBTOTAL(3) \$180			

SUBMITTED BY			Comp	Complete (if applicable)	
Typed or Printed Name	ted Alysia A. Finnegan			Reg. Number	48,878
	alipia 9 fing	Date	04/25/2002	Deposit Account User ID	

APR 2 9-2002 · Application Number: 09/762,794 03/23/2001 Filing Date: Lowe, R. S. et al. First Named Inventor: 1636 Group Art Unit: Guzo, D. Examiner Name:

Attorney Docket Number: 20276P

FIRST CLASS MAIL CERTIFICATE

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO: ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, D.C. 20231, ON THE DATE APPEARING BELOW.

MERCK & CO., INC.

MAILED BY Olypin (1)

_ DATE <u>4/25/02</u>



United States Patent and Trademark Office

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
WWW.USDIO.QOV

FIL FEE REC'D ATTY.DOCKET.NO DRAWINGS TOT CLAIMS IND CLAIMS APPLICATION NUMBER FILING DATE GRP ART UNIT 20276P 230 09/762.794 **CONFIRMATION NO. 1127** APR 2 9 2002 JOCKETE. **FILING RECEIPT** 000210 MERCK AND CO INC OCT 02 2001 P O BOX 2000 OC000000006591549* RAHWAY, NJ 070650907 ARBARA RFI'

Date Mailed: 09/24/2001

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Robert S. Lowe, North Wales, PA; Kathrin U. Jansen, Doylestown, PA; Joseph G. Joyce, Lansdale, PA; William L. Mcclements, Doylestown, PA; James C. Cook III, Lansdale, PA; Jessica Ching-Yee Ling, Bensalem, PA; Michael P. Neeper, Collegeville, PA; RECEIVED

MAY 0 6 2002

TECH CENTER 1600/2900

Domestic Priority data as claimed by applicant

THIS APPLICATION IS A 371 OF PCT/US99/17931 08/10/1999 WHICH CLAIMS BENEFIT OF 60/096,638 08/14/1998

F reign Applications

Pr jected Publication Date: N/A

Non-Publication Request: No

Early Publication Request: No

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on the date appearing below.

By alips Date 4/25/02

Title

Protein delivery system using human palillomavirus virus-like particles

Preliminary Class

435

Data entry by : MOHAMMED, KEDIJA

Team : OIPE

Date: 09/24/2001

LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Secti n 184 Title 37, Code of Federal Regulations, 5.11 & 5.15 GRANTED The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN 5000 FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all 1000 for the phrase of the p LICENSE FOR FOREIGN FILING UNDER

FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all 900 applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15 (b).

PLEASE NOTE the following information about the Filing Receipt:

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved." "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 500 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."
- The title is recorded in sentence case.

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents Office of Initial Patent Examination Customer Service Center Washington, DC 20231